Orforglipron
ALSO KNOWN AS · LY3502970
A non-peptide, small-molecule GLP-1 receptor agonist taken as a daily tablet with no food or water restrictions — a structural departure from every injectable in the class.
Why it matters
Because it is not a peptide, orforglipron avoids the gut degradation problem that forces oral semaglutide to be dosed with a permeation enhancer on an empty stomach. Manufacturing a small molecule also sidesteps the peptide-synthesis capacity constraints that have limited supply across the class.
Clinical evidence
Phase 2 results reported weight reductions in the region of 9–15% at 36 weeks depending on dose, with a gastrointestinal adverse-event profile consistent with injectable GLP-1 agonists. Phase 3 readouts are ongoing.
PRIMARY SOURCES
- 01Orforglipron Phase 2 in obesity— New England Journal of Medicine
Educational reference only. Trial figures are protocol-condition means, not individual predictions. Investigational compounds are not approved medicines and have no legitimate consumer supply route.